Pfizer Q4 2024 Earnings Report

Key Takeaways

Pfizer delivered strong Q4 2024 results, reporting $17.8 billion in revenue, a 21% year-over-year operational increase. Adjusted EPS was $0.63, up from $0.10 in Q4 2023. Growth was driven by increased sales in oncology, Eliquis, and the Vyndaqel family, though partially offset by a decline in Comirnaty revenue.

Total Revenue

$17.8B

Previous year: $14.2B

+24.7%

EPS

$0.63

Previous year: $0.1

+530.0%

Cost of Sales

$5.91B

Previous year: $7.56B

-21.9%

SG&A Expenses

$4.27B

Previous year: $4.58B

-6.6%

R&D Expenses

$3.04B

Previous year: $2.82B

+7.8%

Gross Profit

$11.9B

Previous year: $5.66B

+109.5%

Pfizer Revenue

Pfizer EPS

Pfizer Revenue by Segment

Pfizer Revenue by Geographic Location

Forward Guidance

Pfizer reaffirms its 2025 guidance, expecting revenue between $61-64 billion and adjusted EPS of $2.80-$3.00, with continued cost-saving measures and product growth outside COVID-related sales.

Positive Outlook

Expected 2025 revenue in the $61-64 billion range.
Projected adjusted EPS between $2.80 and $3.00.
Continued cost realignment program targeting $4.5 billion in savings.
Growth expected from non-COVID products including oncology and Eliquis.
Manufacturing optimization program on track for cost savings.

Challenges Ahead

Declining COVID-related revenue expected to impact total revenue.
Some products facing generic competition leading to revenue declines.
Supply constraints affecting oncology biosimilars.
Declining demand for Abrysvo due to reduced vaccination rates.
Lower Xeljanz sales due to market shifts and pricing pressure.

Revenue & Expenses

Visualization of income flow from segment revenue to net income